key: cord-1011733-47vs8mdq
authors: Kaplan, Bonnie
title: Seeing through health information technology: the need for transparency in software, algorithms, data privacy, and regulation(*)
date: 2020-10-09
journal: J Law Biosci
DOI: 10.1093/jlb/lsaa062
sha: 64804d07caadbbe8af07ae30010eba2f115a16e1
doc_id: 1011733
cord_uid: 47vs8mdq

nan

Big data and arti cial intelligence (AI) algorithmic decision-making are becoming more common in healthcare as they are in other sectors. Improvements in both data protection and access, as well as in algorithms, for purposes as di erent as predictive policing, assessing government performance, democratic deliberation, scienti c research, news reporting, and healthcare provision are hoped for through increased of that training, and trainers, also may be unknown. Further, it also can be very di cult to assess the underlying data. 1 There are many ways, then, that it is di cult to know how and why an algorithm gives the results it does, resulting in a black box that leads to informational asymmetries so that how it was developed, trained, or works, or gives the results it does is not known to those using or a ected by it. That makes assessing the algorithm and associated ethical considerations, risks, and responsibilities challenging. 2 Transparency, explainability, interpretability, testability, understandability, identi ability of inherent biases or outright errors, correctability, accountability all are compromised, yet all are considered fundamental to accepting algorithmic recommendations and to human rights (e.g., the EU's General Data Protection Regulation (GDPR). 3 ).

Electronic records systems and decision support-hold harmless, 'gag' clauses, liability, and IP Lack of transparency a ects not only AI algorithms, but also complex systems, such as EHR systems for ordering, communicating, storing, and retrieving clinical information. For example, clinical record data entry and record keeping includes ordering a patient's medications. This can involve automated dosage calculations based, in part, on the patient's weight. The calculation may seem straightforward, a simple algorithm to compute a formula, though there can be errors due to incorrect input, malfunctioning so ware or hardware, erroneous formulas, inconsistencies in how to record either the weight or the medication, di culty of reading (or even nding) the result amid other information displays, and the like. 4 It can be di cult to know whether the resultant calculation is correct, especially if it is not wrong enough to be an obvious error, yet o enough to seriously harm a patient. (Consider how important even a very small error might be to a very small patient, such as a premature infant.) How well tested and vetted is the result that might be produced? How transparent is the calculation? How possible is it to examine the so ware, which is likely protected as IP? Clinicians are presumed to be responsible for detecting if there is an error, whether in such a formula or what information it displays. The system vendor contract may include clauses that hold the vendor harmless regardless of cause of error and instead place sole responsibility on the clinician, who is considered a 'learned intermediary' . EHR so ware is not regulated by the Food and Drug Administration (FDA). Consequently, this so ware is not tested for safety and e cacy. Hold harmless clauses make clinicians 

liable for any errors while they are kept ignorant of information that might help them know there may be errors. 5 Further, as these systems become the standard of practice, clinicians also can be liable for ignoring system warnings and alerts as well as for using them. 6 To protect IP, other contract clauses may prevent a clinician who suspects or detects an error from showing the screen to others to alert them to the possible so ware error. 7 The American Medical Informatics Association considers such practices unethical. 8 Nevertheless, EHR vendor contracts are reported to contain such clauses, but the contracts, too, are considered IP, so cannot be examined to verify these claims. Even when they are available, nding these clauses can be exceedingly di cult. The vendor contract at Presbyterian Hospital of Dallas, the public hospital where the contract was obtained through a freedom of information request a er the rst US Ebola case was diagnosed there in 2014, was over 3000 pages. Further, because of the 'joint and several clause', the non-disclosure and hold harmless clauses may be buried in one of many contract footnotes. 9 Contract provisions that broadly shield both the contract and the so ware to protect IP, in the words of the Westat report for the O ce of the National Coordinator for Health Information Technology (ONCIT or ONC), impede the ability 'to compare di erent EHR technology developer systems, provide access to researchers, or even address possible patient safety concerns' . 10 Transparency, and therefore, patient safety, are compromised.

Now expand these concerns about such relatively simple parts as dosage calculations to the entire system. Consider AI algorithms involved in patient monitors and what alerts should be produced about, for example, a patient's heartbeat. Consider predictive algorithms, ranging in kind from the long-used Apgar scores to assess newborns' health and potential for infant mortality, rst developed in 1952, or computer-based scoring systems, available since the 1980s, that rate severity of disease and prognosis for patients in intensive care, including the most recent ones based on machine learning. Consider the many clinical decision support systems that display anything from reminders that a patient is due a u shot to di erential diagnoses or medication and treatment recommendations.

Care can be compromised if such algorithms are shrouded in secrecy. For example, it would not have been possible to discover that a widely used commercial algorithm resulted in Black patients not receiving needed care. Only when it was studied was it realized that the algorithm predicted healthcare costs as a proxy for illness, and so falsely concluded that Black patients were healthier than White ones when they were not. 11 Only a few vendors dominate the market. Among the disadvantages to this monoculture is that inherent problems become widespread. 12 However, among the advantages is that widespread use could allow for widespread sharing of information. That sharing, though, would have to be done informally (or by notifying the vendor) because of the contract 'gag' clauses mentioned above that protect IP. Moreover, whatever the faults of the ONC EHR certi cation system (required to meet what were, from the 2009 HI-TECH Act EHR Incentives Program, called 'meaningful use' requirements and now called 'promoting interoperability' 13 ), at least more eyes are on these systems Perhaps this will lead to more transparency, perhaps not. Vendors, insurers, and suppliers (e.g., pharmaceutical companies and bene ts managers) keep their data, so ware, and pricing structures proprietary. 14

The particularly sensitive nature of health data is recognized internationally so that health data are given special protection. 15 It is imperative to protect privacy while allowing data to be used for bene cent purposes such as patient care, research, and public health. Current law and regulation do neither. These legal tools were not established to promote research or improve health 16 and were based on older technologies in ways that make them outdated. 17 As new technologies rapidly develop, one's data are more and more interdependent with others', and understandings of privacy undergo change, making current law inadequate, obsolete, and fragmented, whereas ethical and social issues warrant far more extensive discussion and a variety of approaches. 18 

Telehealth, telemed, medical devices-regulatory gaps So far, the focus has been on so ware that collects and processes data. So ware works by processing data, and then producing results that may be used as more data for more processing. In addition to data being directly entered into health records in clinical settings, data are generated by people going about their daily lives using devices and so ware that also rely on data. Much of that data can be related to health, yet it is not regulated or protected as health data. As the Chairwoman of the Federal Trade Commission (FTC) noted in 2013, there is little interest in broader data protection principles. Healthcare tends toward collecting all data. 19 So do commercial entities, as discussed below. Telehealth and mHealth (mobile/smart phone) commercial devices, wearables, personal assistants, or service and assistive robots o en come under little regulatory scrutiny or vetting other than through a marketplace of consumers who are unaware of potential issues. These commercial devices generally are not regulated as medical devices, which can create problems of both data and so ware accuracy and reliability. The FDA tests only what it considers a 'medical device', EHR and decision support systems, 20 and most consumer products, including healthcare apps, are not classi ed as medical devices, nor are they tested for safety and e cacy. 21 How and what can be tested has been in ux, with new directions recently developed for certifying vendors instead of products. 22 Other US agencies regulate di erent aspects of these technologies. The Federal Communications Commission regulates only the transmission of information between devices. The FTC regulates only vendor compliance with their user agreements, which are anything but negotiable or easily understandable by users. 23 The Health Insurance Portability and Accountability Act (HIPAA) regulates only health information collected during clinical encounters with covered entities (i.e., those directly involved in traditional healthcare delivery); 'covered entities' does not include popular devices, wearables, or social media, or communication data that can reveal personal health information. 24 This fragmentation results in uncertainty over which regulators have jurisdiction over what. Di erent state laws, international regulations, and guidelines by state medical boards and professional societies only add to the confusion, 25 as do di ering practices characterizing di erent areas of government healthcare delivery (e.g., the military, Indian Health Service, Veterans Administration).

The burden, then, is entirely on clinicians, patients, and other consumers who may lack the knowledge to detect problems, making clinicians liable and consumers and patients vulnerable. Even for those who are knowledgeable, lack of transparency in user agreements, algorithms, communication protocols, etc. make a determination timeconsuming if even possible. One of these burdens is evident in relying on privacy policies.

Privacy 'protections'-user agreements, privacy policies

One widespread means of privacy protection is through a notice-and-consent approach that presumably gives control to the person involved through end-user agreements. These agreements lack transparency and compromise privacy. Less than one-third of such agreements for popular mobile phone health applications (apps) lack privacy policy statements, whereas the rest do not address the speci c app. Those that exist are written in nearly incomprehensible language, in tiny print, with the privacy sections (if any) buried in much other material. 26 There is little guarantee that the policy will be followed, or that there will be sanctions if it is not. Not surprisingly, people neither read these policies nor understand them if they do. 27 They have little choice but to accept the agreement as is, or not use the device or app, raising issues about consent. Many have no idea that what they consider health information is not protected by privacy regulation, so their data may be sold, aggregated, or used in other ways without their permission or knowledge. This also is the case in social media, such as when people post to Facebook, use ancestry and genetic websites, or shop online. Sometimes they explicitly provide information relating to their health, other times their health status may be inferred by various opaque algorithms. 28 Many people are not aware that what they are posting is not protected as health information, or that the agreements they clicked on at one time gave permission for whatever they post to be used in whatever ways the company involved wishes. 29

Privacy 'protection'-HIPAA, Common Rule, and regulatory gaps In fairness, this is not the fault only of complex and opaque user agreements, but also of the lack of transparency surrounding the regulatory divisions mentioned above and the complexity of privacy protection regulation. Fragmentation plagues both popular understanding and health data protection. Health data privacy is regulated through HIPAA (for clinical data), the Common Rule (for research data), and special regulations for some categories of data, such as for minors, genetic testing, biobanking, or mental illness. 30 combined in ways that may lead to re-identi cation or that implicate people other than the one's represented in the data. These regulations were designed for clinical and small-data studies, not for an era of big data and large-scale data integration. 31 It has been recognized for years that individuals and organizations believe more is protected than it is, 32 creating 'an illusion of protection' . 33 Even for supposedly protected data, individuals may be required to sign authorizations to release data for billing and other, more nebulous purposes. They probably are unaware that various data protections do not apply for public health purposes, such as the COVID-19 outbreak 34 or to track rabies, opioid use, sexually transmitted diseases, or gunshot wounds. 35 Common public understanding of data ownership, data protection, and of 'de-identi cation' does not match the legal understanding of the many ways data is not protected or under individual control. 36 Because the Common Rule was not designed to protect deidenti ed data, 37 permission is not required to use such data for research, so people may become research subjects without their knowledge. 38 Moreover, health-related data also may be identi ed or used in other ways: for example, law enforcement, the military, commercial and public databases, and newborn testing results may include identi ed deoxyribonucleic acid (DNA) sequences. 39 Combinations of data about a person are known to be used for reputation scoring, credit ratings, targeted marketing and price di erentiation, insurance sales and rates, employment decisions, welfare bene ts, and policing. 40 Each of these involves proprietary databases and algorithms, and so lacks accountability because obscured through IP protections. 41 health 51 and more detailed information for personalized medicine. They mix patientgenerated data from various apps and social networks with patient record information, either through voluntary data donors 52 or through partnerships between healthcare organizations and large technology companies. 53 Without knowing more about these activities, including how data are protected and how analyses are used, patients can be concerned about the privacy and security of data, leading some to withhold or misrepresent data, or to not seek care. 54 Consequently, there are omissions and inaccuracies in medical records databases concerning variables, such as race and ethnicity or disability, crucial for precision medicine. 55 In general, we have little information about how accurate or representative databases are, and therefore cannot readily judge whether analyses based on them are skewed. 56 We also may not know what data are used inappropriately as indicators or proxies, which also can cause biases and, consequently, poor care, as illustrated above. 57 Together with the di culties of clearly separating research data from clinical data from genetic data from behavioral health data, data protection and data governance are becoming increasingly di cult. They rely on fuzzy boundaries and, in the US, on an outdated sectoral regulatory approach. 58 Blurring of these various boundaries has implications for data governance and data ownership, for patients, clinicians, and all individuals.

Data governance is complicated. As outlined above, clinical data, research data, and data from commercial devices or social networks, data storage and data transmission, all are regulated di erently, to the extent there is regulation at all. As noted above, distinctions between these categories, though, are blurring. 59 When is it possible to distinguish between patient data for patients on various research protocols when those patients also are treated for co-morbidities that might a ect research results? What should be done with patient-generated data that is fed into medical records and also stored on the patient's app or uploaded to a vendor's cloud or a social network site? Moreover, each state, as well as each branch of various governmental healthcare providers (e.g., military, Indian) also has its own set of regulations. What happens when patients cross institutional or jurisdictional lines? Large healthcare organizations employ data governance specialists. Patients and small practices fend for themselves, assuming they know that fending is needed.

Aside from one person's actual health-related data, collateral data, which provides information about other people, also is at risk, creating additional privacy concerns. These privacy concerns likely are opaque to all a ected people. Location tracking, for example, is easy with many devices that run health-related apps. Like 'friending' or other ways of indicating connection, location tracking can reveal where someone goes, with whom the person associates, what activities and organizations the person attends and with whom, thereby also providing information about these other people, without their knowledge. In-home services-ranging from bedside monitors and other telemedicine applications to fall-detecting sensors, automated pill-boxes, virtual assistants, and assistive robots-collect all sorts of private information, not only about a patient, but about anyone in range. 60 Further, people share devices. Without solid authenticity checks, data related to one person may be attributed to someone else.

In addition, data collected from some can a ect others from whom no data are collected. It can be used for inferences and predictions about people who are related genetically to data subjects, are members of the same ethnic group or community, or are people who otherwise share data patterns of interest. People may be grouped according to algorithmically based characteristics and decisions based on those groupings, all without their knowledge or consent. Such predictions may violate privacy, sense of identity, or otherwise be problematic for people and groups about whom inferences are made. 61 Of course, devices may be stolen or hacked, communications may be comprised, cloud storage for the volumes of data being collected can be available to the service provider, and patient record systems can be (and have been) subject to ransomware attacks and data the . Although these vulnerabilities are receiving more attention and news coverage, they are not generally known. Here, too, more transparency is needed.

Data ownership and sales also require more transparency, clarity, and scrutiny. Patients do not own their data, or do they? Ownership depends on who holds the data and in what form. 62 Generally, while patients may own the information within their medical records, the clinician or facility owns the physical form in which those records are kept. The distinction is lost on many people. Hospitals, pharmacies, and health insurance companies sell data patient data, 63 though, here, too, ownership can be unclear. What access and ownership claim to electronic record systems do vendors or cloud services have, and how easily can hospitals use or control the data generated from their own patients' records? Although social networks and health app vendors own and sell data provided by their users and customers, as mentioned, their data policies are o en not stated clearly and may change or be violated without much notice.

Regulation does not protect data related to physicians or other clinicians. Although some information about them is public, such as their training and licensure, because it is considered in the public interest, other information may compromise them or their patients. Selling prescription data raises these concerns. Data aggregators combine the American Medical Association's (AMA) Physician Master File to identify individuals' prescribing practices. But people do not know that their prescription data are aggregated and sold, and that physician pro les are created based on their prescribing practices for the purposes of pharmaceutical marketing. Physicians wishing to curtail intrusive marketing can opt out, if they know about the AMA's Physician Data Restriction Program, but this does not cover prescribers who are not physicians. Moreover, the AMA permits this database to be mined by pharmaceutical company employees other than sales representatives. Such data can reveal who prescribes abortifacients or other controversial medications, putting all parties at risk. Targeting clinicians, whether for marketing or other purposes, on the grounds that these data are protected as speech, can compromise both them and their patients. 

What happens to the data?

As suggested above, all data can be considered health data. 65 Various data and sources have been used for healthcare, public health and epidemiology, 66 research, and other bene cent purposes. 67 They have been used in controversial health-related ways, as Facebook does for suicide prevention, 68 or for tracking possible contacts and contagion during an epidemic, 69 or for verifying (or denying) eligibility for welfare bene ts. 70 They have been used in more questionable ways not clearly related to healthcare, as in algorithmic-based decisions regarding targeted marketing, credit, insurance, employment, housing, or policing, 71 thereby causing group and societal as well as personal harms. 72 Even when used for health research, if data are de-identi ed, research subjects have no way of knowing what is done with it, and so may become research subjects for that, and later, research without their knowledge or consent. 73 Further, when combined with other data, these individuals may become identi able.

Consequently, it is di cult, if not impossible, to know about what happens to particular data a person either knowingly or unknowingly provides or inadvertently sheds while doing other things. By the time data is collected, aggregated, sold, repackaged, combined with other data and sold again, and again, and again, no one can know, let alone consent, to how that data will be used. Among the uses is training predictive algorithms or making various predictions about individuals, not visible to most people, whether or not they personally contributed the data or agreed to its use in this way. This opacity further contributes to power asymmetries. 74 Additional concerns arise when data stores are breached and considerable personal data, including data that can be health-related, is accessed, stolen, or locked up for ransom. There is a lucrative black market in health data, 75 and the Federal Bureau of Investigation has warned that health data vulnerabilities could leave the US open to cyber or biological attacks. 76 Individuals may not know about data breaches or attacks until quite some time a er they occur, or may not know at all, but there is little recourse and remedy even if they are quickly noti ed. They also likely are not informed about threats due to malware, lack of encryption, insecure data storage and transmission, or how they can better protect themselves. 77 It is no wonder patients value privacy, risk minimization, data security, transparency, control, information, trust, responsibility, and accountability. 78

Lack of transparency characterizes numerous aspects of information technologies used in healthcare or that involve health-related data, such as algorithms, telemedicine, EHR systems, mHealth, wearables, devices, and social networks. The issues involve aspects of contract, IP, privacy regulation, liability and malpractice, First Amendment (data as speech) law, consent and authorizations, computer security, patient-(and others) generated data, and data ownership. In various ways, all these concerns a ect and re ect market incentives, organizational policies, social norms, ethical considerations, technical knowledge, disciplinary practices, practitioner behavior, and public responses.

Because transparency cross-cuts and combines so many areas, a multifaceted interdisciplinary approach can bring proposals and solutions from various perspectives to attention, identify and implement best practices, and contribute to public discussion about ethically, legally, socially, and politically acceptable ways to address them. Interactionist and sociotechnical theoretical analyses can be brought to bear concerning how information technologies and social systems involve multiple interdependent elements acting as a holistic dynamic network. 79 Patients, clinicians (and their parallels in other sectors), employees, and the public should be informed about organizational policies pertaining to how and what decisions are made that directly a ect them, their health and safety, and their privacy. They can work to change policies and practices, and, to the extent patients and clinicians have a choice, they can apply market pressures that encourage provider organizations toward desired practices. This requires more than regulatory and policy change. It also requires tapping scholarship and practice in multiple areas, and public attention and involvement. Some thoughts follow, meant to stimulate other ideas and more discussion.

Health information technology so ware IP protections should not be used as legal shields to prevent accountability and liability for health, or other, information technologies. Patient safety and public harms should not be compromised by errors hidden by contracts, trade secrets, copyrights, or vague patents. Known problems should quickly be disclosed and addressed, and those detecting them (including developers and users) should not be penalized for attempting to get them corrected. Unregulated commercial apps related to healthcare should be subject to patient safety and privacy protections and law suits. Legal scholarship in this area is robust and thoughtful in addressing how and whether vendors and those producing 77 information technologies should be held responsible for so ware and hardware errors. Broader interdisciplinary and public discussion would be bene cial.

Organizational policy and practices also can help. Administrators responsible for purchasing information technologies should be well versed in assessing contracts and liabilities, or rely on experts knowledgeable in these areas. That requires more legal training in these speci c areas for risk managers and organizational attorneys advising on these complexities. Additionally, purchasers can require, and vendors provide, information on what data sources, processes, methods, and testing are used to produce and update algorithms. Journalists, patients, courts, and other legitimately interested parties should have a mean to obtain this information as well, with suitable attention to preventing commercial or personal harm. To the extent possible, healthcare organizations and practices can purchase electronic record and decision support systems that provide easy to understand justi cations and explanations of how conclusions and recommendations were reached. As has long been known, clinicians are more likely to trust such systems or to at least nd them acceptable. 80 Administrators should take advantage of the knowledge of information technology departments, chief medical information o cers, and the medical informatics community that has been addressing such issues both through national policy, organizational practices, and scholarship for decades. They should also support on-going reassessment of their policies, practices, and information technologies for evidence-based adjustments. Legal scholarship, too, should periodically revisit these areas, as conditions change and the empirical base develops related to how regulations and laws play out in practice.

identi cation has been considered inadequate legal protection for some years. 83 In other areas, and also for the release of protected data, it relies on problematic notice and consent practices. However, unlike the GDPR, it does not take a broader view of what constitutes 'health data' and focuses on 'downstream' models of data protection, such as breach noti cations and data disclosure rather than on how data are collected and used. 84 The GDPR does not have a long enough history to judge its long-term e ects, but both its predecessor and US sectoral privacy law in healthcare, nance, and education do. Based on that history, privacy protections could be harmonized across types and sources of data and regulatory agencies, with some caveats. Experience indicates problems with checklist-type regulations such as HIPAA. Complex, weighty, topdown, fragmented regulation can sti e innovation and increase opportunities for circumvention and arbitrage. They result in symbolic structures that use compliance as a ceiling, rather than oor, for privacy protection. Compliance has become a rigid, rulebased regime rather than a spur to more ethical norms and innovation in law, product design, contracts, or much else. 85 That makes organizational policies and practices all the more important.

Privacy protections do not protect privacy or allow for bene cial data use. Informed consent is neither very informed nor very consensual. Better alternatives are needed. Legal scholarship has provided a number of possibilities. Various organizations have published standards and guidelines that could help, and professional organizations include social considerations like privacy in their ethics codes. 86 However, privacy protection depends on more than regulation or aspirational statements. Privacy by design and computer science data obfuscation methods of privacy protection could be required by so ware and database developers and purchasers. Organizational attention and investment, too, are needed. This includes not only technical expertise, but also expertise in data governance. The knowledge of privacy protection safeguards should be part of educational programs for individuals responsible for organizational policies in these areas. Employees need to know that privacy permeates organizational culture and is taken seriously beyond simple compliance, and to know how to do it. HIPAA Similarly, far more attention is needed to improve cybersecurity on personal, institutional, national, and international levels. Ransomware attacks and privacy breaches indicate the need for improved cybersecurity and data protection, a need that will be more crucial as devices for mHealth, wearables, implantables, and telemedicine communicate with AI algorithms, patient records, assistive robots, automated personal assistants, and databases. Timely noti cation of data breaches, signi cant penalties for negligent security practices, and remedies to those a ected could be made more e ective deterrents. Especially because healthcare and public health as well as information technology have long been considered critical infrastructures by the Department of Homeland Security, 87 the ONC could make strengthened data protection and cybersecurity practices necessary for certifying electronic record systems.

Organizational practices and policies can help address some of the issues. Vendors and purchasers should make clear to all concerned how data ownership, transfer, and use are handled. Healthcare organizations should develop guidelines for information technology selection and use that meet high standards of patient safety, cybersecurity and privacy, and ethics. They should carefully vet devices they purchase or recommend to patients so that clinicians and patients can be con dent of proper functioning and privacy protections. Employees and patients should be assisted in learning what they need to know to responsibly use these technologies.

Increased transparency is crucial to address many concerns related to information technologies. Without greater awareness, understanding, and discussion, change is di cult and accountability unlikely. Patients, clinicians, practitioners, data managers, legislators, and regulators need to examine the full spectrum of considerations and the tangle that makes them hard to assess. Many proposals address the issues, though there is yet little agreement on solutions. With more transparency, these concerns can be addressed better and regulations made more simple, harmonized, exible, and e ective.

But regulatory change is not, in itself, enough. Law and regulation both create and are created by other social and political considerations. Market incentives, organizational policies, social norms, ethical considerations, technical knowledge, academic theories, disciplinary practices, and law and regulation all interact with each other in ways that make it di cult to address any one outcome by any one approach. Research, methods, theories, and practices in a variety of disciplinary areas are addressing issues of concern. Knowledge from multiple elds-among them, ethics, surveillance studies, computer science and information systems, law, healthcare, organizational studies, medical informatics, social sciences, and patient safety-needs to be integrated, and further studies conducted to examine communities of practice to expand understanding and improve policy and practice through consideration of related ethical, legal, and social issues in healthcare. 88 Just as technologies are converging, insights from these elds need to converge to address changing the regulatory and legal regime, as well as the commercial, social, and organizational environments.

Journalists and scholars have been doing an excellent job of informing each other and the public about issues and suggesting creative solutions. But no one solution will suit everyone or every place, or address all issues. This paper presents some possible directions with the hope of stimulating others. A number of di erent approaches working together are needed, requiring exibility and various alternatives. The pieces can be addressed individually, but they also need to be integrated into a working whole that is periodically assessed because conditions change over time. Market and government structures that allow this exibility will result in more choices. As we develop new approaches to healthcare and technological innovation, we need to think broadly, because all data are becoming useful as health data, and that means that these issues a ect everyone and nearly everything we do. 

All Your Data is Health Data: and Big Tech Has it All

What Is It, and Where Is It Going?

Executive O ce of the President, supra note 48

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering

The Common Rule and Research with Data, Big and Small

Bad Actor's Getting Your Health Data is FBI's Latest Worry

Additionally, when these technologies are used for other purposes, they also collect data that can reveal people's health information, such as when communication companies track users' locations or personal contact data. Consensus is growing that US regulation is outdated and inadequate, both for privacy protection and for public health and research. Regulation di ers according to the kind, source, and use of data; location and means of data collection; and type of technology used. It does not su ciently address areas of data ownership, secondary (and tertiary, etc.) use, consent, and the special vulnerability of health-related data. Existing regulations impede the ability to collect, store, aggregate, link, and transmit health data broadly and repeatedly for legitimate health, technical, strategic, policy, and economic purposes, 81 and to access data for important clinical, public health, and quality assurance reasons even when there is little privacy risk. 82 Like its international counterparts, US privacy regulation depends on deidenti cation to preserve privacy

Arti cial Intelligence in Medicine: Weighing the Accomplishments, Hype, and Promise, 28 Y M I 257

Cross Sector Data Sharing: Necessity, Challenge, and Hope, 47 P . H & L

Broken Promises of Privacy: Responding to the Surprising Failure of Anonymization

Health Research, Data Protection, and the Public Interest in Noti cation

Ari Ezra Waldman, Privacy Law's False Promise, 97 W U

United States Government, Department of Health and Human Services, O ce of the National Coordinator for Health Information Technology, Nationwide Privacy and Security Framework for Electronic Exchange of Individually Identi able Health Information

Privacy Framework

AMIA's Code of Professional and Ethical Conduct